ArticleAdvanced healthcare materials2026
Interfacial Bioengineering of Dynamic Networks Hybrid Hydrogel for Programmed Intervention in Oral Precancerous Epithelial States.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interfacial Bioengineering of Dynamic Networks Hybrid Hydrogel for Programmed Intervention in Oral Precancerous Epithelial States.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A major challenge in precision medicine is the development of advanced biomaterials for targeted intervention in precancerous states. Here, we introduce an interfacial bioengineering strategy to construct a dynamic network for programmed intervention in epithelial precancerous lesions. Our dual-bioinspired hydrogel, MSA@PGel (macrophage membrane-coated and salvianolic acid B [SAB] /5-aminolevulinic acid co-loaded liposomes embedded in a polydopamine-based gel), leverages both the powerful wet adhesion of mussels and the immune-targeting capabilities of macrophages. The material's core innovation lies in its dynamic catecholato-Fe
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.